Introduction
Achieving greater reductions in cardiovascular risk
Statins as the cornerstone of drug therapy for dyslipidemia
Focus on high-density lipoproteins in reducing cardiovascular risk
High-sensitivity C-reactive protein, inflammation, and cardiovascular risk